StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab cash

Cash and short-term investments held at the end of each period.

BioNexus Gene Lab's cash was $1.23M at Jun 30, 2026. For fiscal 2025 it was $2.38M, down 17.4% from the year before. The highest annual figure on record is $4.52M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.38M-17.4%
FY2024Dec 31, 2024$2.89M-36.1%
FY2023Dec 31, 2023$4.52M+113.2%
FY2022Dec 31, 2022$2.12M-0.2%
FY2021Dec 31, 2021$2.12M-23.8%
FY2020Dec 31, 2020$2.79M+224.5%
FY2019Dec 31, 2019$859.08K-31.8%
FY2018Dec 31, 2018$1.26M+50.2%
FY2017Dec 31, 2017$839.15K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.23M-19.8%
Q1 FY2026Mar 31, 2026$1.34M-36.0%
Q4 FY2025Dec 31, 2025$2.38M-17.4%
Q3 FY2025Sep 30, 2025$1.15M-72.1%
Q2 FY2025Jun 30, 2025$1.54M-71.6%
Q1 FY2025Mar 31, 2025$2.09M-52.9%
Q4 FY2024Dec 31, 2024$2.89M-36.1%
Q3 FY2024Sep 30, 2024$4.14M-32.7%
Q2 FY2024Jun 30, 2024$5.41M+207.8%
Q1 FY2024Mar 31, 2024$4.44M+124.9%
Q4 FY2023Dec 31, 2023$4.52M+113.2%
Q3 FY2023Sep 30, 2023$6.15M+320.4%
Q2 FY2023Jun 30, 2023$1.76M+31.2%
Q1 FY2023Mar 31, 2023$1.97M+7.0%
Q4 FY2022Dec 31, 2022$2.12M-0.2%
Q3 FY2022Sep 30, 2022$1.46M-14.0%
Q2 FY2022Jun 30, 2022$1.34M-9.6%
Q1 FY2022Mar 31, 2022$1.84M-25.5%
Q4 FY2021Dec 31, 2021$2.12M-23.8%
Q3 FY2021Sep 30, 2021$1.70M-22.4%
Q2 FY2021Jun 30, 2021$1.48M+15.2%
Q1 FY2021Mar 31, 2021$2.47M+77.2%
Q4 FY2020Dec 31, 2020$2.79M+224.5%
Q3 FY2020Sep 30, 2020$2.19M+124.1%
Q2 FY2020Jun 30, 2020$1.29M+12.9%
Q1 FY2020Mar 31, 2020$1.40M+133.8%
Q4 FY2019Dec 31, 2019$859.08K-31.8%
Q3 FY2019Sep 30, 2019$977.15K-31.0%
Q2 FY2019Jun 30, 2019$1.14M+35.9%
Q1 FY2019Mar 31, 2019$597.46K–
Q4 FY2018Dec 31, 2018$1.26M–
Q3 FY2018Sep 30, 2018$1.42M–
Q4 FY2017Dec 31, 2017$839.15K–

More BioNexus Gene Lab figures

See a number that looks wrong?